Topical photodynamic therapy in the treatment of actinic keratoses and Bowen's disease in transplant recipients.

BACKGROUND: Transplant recipients (TR) have a dramatically increased risk for widespread epithelial neoplasms of the skin. Thus, there is a need to treat initial stages of these neoplasms such as actinic keratoses (AK) and Bowen's disease (BD) to prevent progression to invasive and potentially fatal squamous cell carcinoma. Topical photodynamic therapy (PDT) has been proven to be an effective treatment for AK and BD in immunocompetent patients, but no prospective trials in immunocompromised TR have been performed so far. METHODS: Twenty TR and 20 controls with histologically confirmed AK or BD underwent either a single or two consecutive treatments of topical PDT in an open trial. The application of 20% 5-aminolevulinic acid (ALA) for 5 hours was followed by illumination with 75 J/cm2 of visible light delivered at 80 mW/cm2 by an incoherent light source. RESULTS: The overall complete response rates in TR at 4, 12, and 48 weeks were 0.86, 0.68, and 0.48, respectively. The cure rates in both patient groups were comparable at 4 weeks but were significantly lower in TR than in controls at 12 and 48 weeks (P<0.05). Side effects included erythema, edema, and crust formation after illumination. Cosmetic results were excellent without scar formation or alterations in pigmentation. CONCLUSIONS: Topical PDT with 20% 5-ALA is an effective and safe treatment for AK and BD in immunosuppressed TR, with initial response rates comparable with those in immunocompetent patients. It is particularly useful in TR because of the possibility for repeated treatment of large lesional areas.

Regional citrate anticoagulation using a citrate-based substitution solution for continuous venovenous hemofiltration in cardiac surgery patients.

OBJECTIVE: To evaluate the feasibility, efficacy, safety and side effects of routinely performed continuous venovenous hemofiltration (CVVH) with regional citrate anticoagulation using a citrate-containing substitution solution as compared with conventional systemic low-dose unfractionated heparin-anticoagulation in postoperative cardiac surgery patients. DESIGN/SETTING: Database review of all patients on CVVH during a three-year period at a cardiovascular intensive care unit of a tertiary referring university hospital. PATIENTS: Patients who had undergone cardiac surgery with acute or chronic renal failure were studied. Thirty-seven citrate CVVH courses in 31 patients (January to November 2000) and 59 heparin CVVH courses in 50 patients (1998 and 1999) had been undertaken postoperatively. Indications for hemofiltration were acute renal failure in 24 and chronic renal failure in 7 of the citrate patients, and acute renal failure in 44 and chronic renal failure in 6 of the heparin patients. INTERVENTIONS: CVVH with either regional citrate anticoagulation using a custom-made citrate-based substitution solution or unfractionated heparin anticoagulation. MEASUREMENTS: The following parameters were measured: median filtration time, hemofilters used per day, differences in creatinine and blood urea levels as opposed to baseline, blood loss within the first 24 h of hemofiltration, incidence of bleeding-related resternotomies, acidosis, and alkalosis. RESULTS: No significant differences in any of the measured parameters were registered. No serious electrolyte imbalance was observed in either group. Furthermore, the two groups did not differ in terms of mortality, duration of stay in the intensive care unit or in hospital, and restoration rate of normal renal function. CONCLUSIONS: We conclude that citrate-based regional anticoagulation is effective, safe and easy to use in CVVH following cardiac surgery and might become the first choice for anticoagulation in patients in whom the application of systemic heparin is contraindicated.

Disseminated varicella infection in adult renal allograft recipients: four cases and a review of the literature.

Disseminated varicella-zoster (VZV) infection is a rare complication after renal allotransplantation in adults. We report four patients, among them one with combined VZV and cytomegalovirus infection. The main complications were hepatitis, pneumonitis, and disseminated intravascular coagulation. A review of the literature from 1981 to 2000 revealed 34 additional cases of disseminated varicella infection in adult renal allograft recipients with an overall mortality of 34%. Among these patients 82% suffered from primary varicella, 18% had a reactivation. High-dose acyclovir therapy combined with reduction of immunosuppression lead to reduction of mortality from 53% before 1990 to 22% after 1990. No immunosuppressive drug is significantly associated with a higher risk of disseminated VZV infection. Immunization against VZV in adults is still a matter of controversy. Whereas passive immunization is performed only for prophylactic but not therapeutic purpose, active immunization is routinely performed in children and may also be recommended for adults before renal transplantation.